Mayo Clinic study finds powerful myeloma treatment regimen shows promise for AL amyloidosis

Mayo Clinic study finds powerful myeloma treatment regimen shows promise for AL amyloidosis Two studies published in Blood, the Journal of the American Society of Hematology (ASH), demonstrate preliminary success of an effective multiple myeloma (MM) regimen in patients with AL amyloidosis, a rare and devastating blood disease that results in deposition of damaging abnormal … Continue reading “Mayo Clinic study finds powerful myeloma treatment regimen shows promise for AL amyloidosis”

Mayo Clinic study finds powerful myeloma treatment regimen shows promise for AL amyloidosis

Two studies published in Blood, the Journal of the American Society of Hematology (ASH), demonstrate preliminary success of an effective multiple myeloma (MM) regimen in patients with AL amyloidosis, a rare and devastating blood disease that results in deposition of damaging abnormal protein in critical organs of the body, including the kidneys, heart, liver, and intestines, and shares some characteristics with MM.

Click here to read full press release.

###

Among the research institutions NCI funds across the United States, it currently designates 66 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.

Author: Joe Lovrek

Born in Houston, Raised in Trinity Texas

Leave a Reply